SINGLERA GENOMICS INC.

Company Overview

Singlera Genomics Inc., founded in 2014, is developing and commercializing technologies relating to the analysis of ctmDNA (circulating tumor methylated DNA) for cancer screening, diagnosis and personalized medicine. In particular, high-throughput sequencing of methylated circulating tumor DNA is being used in its assays.

For early cancer detection applications, Singlera has been studying 200,000 healthy individuals since 2008. During the 10 years from 2008 to 2018, about 5% of these people have developed cancer. This long-term database is being used to help develop early cancer detection tests.

Singlera’s technology identifies methylation haplotypes specific to a particular tissue or cell type, and uses this to determine the origins of the ctDNA.

Singlera’s initial liquid biopsy focus is on early colorectal cancer detection, with its PanSeer test. In clinical data released in July 2020 the test was used in healthy individuals and accurately detected five cancer types (stomach, esophagus, colorectum, lung or liver cancer) in 91% of samples from people who were diagnosed with cancer one to four years later. This study was important because it involved samples from patients who were asymptomatic and who had not been diagnosed with cancer. This study was part of the 2008-2018 10-year longitudinal study.

Singlera, together with Yale University, developed a second-generation NIPT assay that it is seeking to commercialize. This test uses NGS to detect chromosomal aneuploidy and measure fetal DNA fractionation. The test has a turnaround time of one day versus up to one week for competing tests.

Company's Business Segments

• Non-Invasive Genetics Testing : This segment offers a range of products and technologies for genetic disease detection, tumors, and monitor the recurrence of high-incidence cancers.